Adakveo (crizanlizumab-tmca) – Medical Benefit Coverage Criteria
Customize your policy alerts
Sign up for sierra health and life Policy 2026D0085L alerts
Get alerted when Policy 2026D0085L changes without checking for updates manually.
Monitor payer policy activity
Clinical policy governing medical-benefit coverage of Adakveo (crizanlizumab-tmca) for members with sickle cell disease under UnitedHealthcare Commercial and Individual Exchange plans. It defines initial and continuation therapy criteria, exclusions, and applicable codes for providers and prior authorization processes.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.